Skip to content

US · OGN · DRUG MANUFACTURERS - GENERAL

Organon & Co. (OGN) intrinsic value and stock valuation

$13.89as of 2026-11-21 · Mkt cap 3.57B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Organon & Co. DCF and intrinsic value

InvestorsCraft values OGN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OGN’s statements →

Organon & Co. Graham Number

Graham Number: $6.85d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Jersey City, NJ 07302 organon.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$6.22B-1% 5y CAGRd
20172025
Net income
$187M-38.7% 5y CAGRd
20172025
Free cash flow
$538M-22.4% 5y CAGRd
20172025
Total equity
$752M-32.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$6.22B$6.4B$6.26B$6.17B$6.3B
Operating income$1.29B$1.49B$1.33B$1.71B$1.92B
Net income$187M$864M$1.02B$917M$1.35B
EPSd$717.1K$3.33M$3.99M$3.59M$5.33M
Operating cash flow$700M$939M$799M$858M$2.46B
Capital expenditure-$-162M-$-351M-$-261M-$-427M-$-488M
Free cash flow$538M$588M$538M$431M$1.97B
Total assets$12.9B$13.1B$12.1B$11B$10.7B
Total debt$8.8B$9.04B$8.93B$9.11B$9.36B
Net debt$8.23B$8.36B$8.24B$8.41B$8.63B
Total equity$752M$472M-$-70M-$-892M-$-1.51B
Cash and short-term investments$574M$675M$693M$706M$737M
Income statement
20252024202320222021
Revenue$6.22B$6.4B$6.26B$6.17B$6.3B
Cost of revenue$2.85B$2.69B$2.52B$2.29B$2.38B
Gross profit$3.36B$3.72B$3.75B$3.88B$3.92B
Research and development expenses$366M$469M$528M$471M$443M
Selling, general and administrative expenses$1.71B$1.76B$1.89B$1.7B$1.67B
Other expenses$10M$0.00$0.00$0.00-$-104M
Operating expenses$2.09B$2.23B$2.42B$2.18B$2.01B
Cost and expenses$4.93B$4.92B$4.94B$4.47B$4.39B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$504M$520M$527M$422M$258M
Depreciation and amortization$353.3M$277M$236M$212M$195M
Ebitda$1.28B$1.6B$1.44B$1.76B$1.98B
Operating income$1.29B$1.49B$1.33B$1.71B$1.92B
Total other income/expenses, net-$-860M-$-679M-$-654M-$-583M-$-386M
Income before tax$425M$807M$673M$1.12B$1.53B
Income tax expense$238M-$-57M-$-350M$205M$178M
Net income$187M$864M$1.02B$917M$1.35B
Weighted average shares outstanding$259.5M$257.1M$255.2M$254.1M$253.6M
Weighted average diluted shares outstanding$260.8M$259.2M$256.3M$255.2M$253.6M
Balance sheet
20252024202320222021
Cash and short-term investments$574M$675M$693M$706M$737M
Net receivables$1.43B$1.49B$1.86B$1.61B$1.51B
Inventory$1.41B$1.32B$1.32B$1B$915M
Total current assets$4.35B$4.35B$4.51B$3.93B$3.76B
Property, plant and equipment, net$1.3B$1.33B$1.36B$1.23B$1.2B
Goodwill and intangible assets$5.28B$6.09B$5.14B$5.25B$5.25B
Long-term investments$0.00$27M$0.00$0.00$0.00
Total non-current assets$8.52B$8.75B$7.55B$7.02B$6.92B
Total assets$12.9B$13.1B$12.1B$11B$10.7B
Accounts payable$952M$1.15B$1.31B$1.13B$1.38B
Short-term debt$56M$64M$55M$57M$55M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.39B$2.72B$2.92B$2.51B$2.6B
Long-term debt$8.76B$8.97B$8.88B$9.06B$9.31B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.73B$9.91B$9.21B$9.34B$9.59B
Capital lease obligations$116M$112M$125M$150M$184M
Total liabilities$12.1B$12.6B$12.1B$11.8B$12.2B
Common stock$3M$3M$3M$3M$3M
Retained earnings$1.11B$1.01B$443M-$-331M-$-998M
Accumulated other comprehensive income (loss)-$-527M-$-649M-$-541M-$-564M-$-513M
Total equity$752M$472M-$-70M-$-892M-$-1.51B
Total investments$0.00$27M$0.00$0.00$0.00
Total debt$8.8B$9.04B$8.93B$9.11B$9.36B
Net debt$8.23B$8.36B$8.24B$8.41B$8.63B
Cash flow statement
20252024202320222021
Net income$187M$864M$1.02B$917M$1.35B
Depreciation and amortization$361M$277M$236M$212M$195M
Stock-based compensation$77M$105M$101M$75M$59M
Change in working capital-$-247M-$-278M-$-155M-$-452M$702M
Accounts receivable$79M$383M-$-212M-$-123M-$-277M
Inventory-$-13M-$-131M-$-230M-$-220M-$-138M
Accounts payable-$-217M-$-157M$163M-$-237M$663M
Net cash provided by operating activities$700M$939M$799M$858M$2.46B
Investments in property, plant and equipment-$-192M-$-351M-$-259M-$-427M-$-488M
Acquisitions, net-$-198M-$-166M-$-2M-$-124M-$-185M
Net cash used for investing activities-$-390M-$-513M-$-260M-$-420M-$-481M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-22M-$-17M$0.00$0.00
Dividends paid-$-88M-$-297M-$-294M-$-290M-$-145M
Net cash used for financing activities-$-561M-$-368M-$-569M-$-433M-$-1.33B
Net change in cash-$-101M-$-18M-$-13M-$-31M$667M
Cash at end of period$574M$675M$693M$706M$737M
Operating cash flow$700M$939M$799M$858M$2.46B
Capital expenditure-$-162M-$-351M-$-261M-$-427M-$-488M
Free cash flow$538M$588M$538M$431M$1.97B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Organon & Co.

        Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.

        CEO
        Joseph T. Morrissey Jr.
        Employees
        10K
        Beta
        1.54

        Explore

        Frequently asked questions

        What is the intrinsic value of Organon & Co. (OGN)?

        Organon & Co. (OGN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OGN undervalued?

        OGN trades at a price of $13.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.